Erratum: Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans (Journal of the Renin-Angiotensin-Aldosterone System (2008) vol. 9 (37-48) 10.3317/jraas.2008.001);Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 1, 2008, Pages 37-48

  Pedersen Bjergaard, Ulrik ^a   Thomsen, Carsten E ^b   Høgenhaven, Hans ^c   Smed, Annelise ^d   Kjœr, Troels W ^c   Holst, Jens J ^c   Dela, Flemming ^e   Hilsted, Linda ^d   Frandsen, Erik ^f   Pramming, Stig ^g   Thorsteinsson, Birger ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Department of Neurophysiology ^*  (Denmark)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^g NOVO NORDISK A S   (Denmark)

Author keywords

Angiotensin converting enzyme; Cognition; Counterregulation; Hypoglycaemia

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; NEUTRAL INSULIN; PLACEBO;

ADULT; APPLE JUICE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DETERIORATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ERROR; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; HYPOTHESIS; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; RISK FACTOR; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; VOLUNTEER;

EID: 42249093866     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2008.001     Document Type: Erratum

References (42)

1. Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:637-48.
2. Høi-Hansen T, Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Risk factors of severe hypoglycemia and occurrence of silent hypoglycemia in patients with type 1 diabetes assessed by Continuous glucose monitoring. Diabetes 2005;54(suppl 1): A153.
3. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-86.
4. Pedersen-Bjergaard U, Pramming S, Heller SR et al. Severe hypoglycaemia in 1076 patients with type 1 diabetes: Influence of risk markets and selection. Diabet Metab Res Rev 2004;20:479-86.
5. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 2001; 357:1248-53.
6. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes. Diabetologia 2003;46:89-96.
7. Nordfeldt S, Samuelsson U. Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:274-8.
8. Zammitt NN, Geddes J, Warren RE, Marioni R, Ashby JP, Frier BM. Serum angiotensin-converting enzyme activity and frequency of severe hypoglycaemia in type 1 diabetes: Does a relationship exist? Diabet Med 2007;24:1449-54.
9. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sørensen TI, Jensen G, Tybjærg-Hansen A. ACE gene polymorphism: Ischaemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997;95:2358-67.
10. Chang L, Ernst T, Speck O, Patel H, DeSilva M, Leonido-Yee M, Miller EN. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 2002;114:65-79.
11. Hepburn DA, Deary IJ, MacLeod KM, Frier BM. Structural equation modeling of symptoms, awareness and fear of hypoglycemia, and personality in patients with insulin-treated diabetes. Diabetes Care 1994;17 1273-80.
12. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon producing tumours. Diabetologia 1983;24 359-65.
13. Appel E, Bayer P, Hajdu P, Palm D, Shofer J, Uihlein M. Determination of plasma catecholamines by means of radioenzymatic labeling and high pressure liquid chromatographic separation. Naunyn Schmiedebergs Arch Pharmacol 1981;315:233-9.
14. Klaniecki TS, Corder CN, McDonald RH Jr, Feldman JA. High-performance liquid chromatographic radioenzymatic assay for plasma catecholamines. J Lab Clin Med 1977;90:604-12.
15. Schwartz TW, Holst JJ, Fahrenkrug J et al. cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 1978;61 781-9.
16. Poulsen K, Jørgensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974;39:816-25.
17. Millar JA, Leckie BJ, Morton JJ, Jordan J, Tree M. A micro assay for active and total renin concentration in human plasma based on antibody trapping. Clinica Chimica Acta 1980;101:5-15.
18. Kappelgaard AM, Nielsen MD, Giese J. Measurement of angiotensin II in human plasma: Technical modifications and practical experience. Clinica Chimica Acta 1976;67:299-306.
19. Bulsara MK, Holman CDJ, van Bockxmeer FM, et al. The relationship between ACE genotype and risk of severe hypoglycaemia in a large population-based cohort of children and adolescents with type 1 diabetes. Diabetologia. 2007;50:965-71.
20. Pedersen-Bjergaard U, Dhamrait SS, Sethi AA et al. Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 Diabetes. Am J Med 2008;121:246E1-E8.
21. DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol 2004;287 E32-E41.
22. Porcellati F, Pampanelli S, Rossetti P, Cordoni C, Marzotti S, Scionti L, Bolli GB, Fanelli CG. Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans. Diabetes 2003;52:2774-83.
23. Heller SR, Amiel SA, Evans ML, Kong MF, Macdonald IA, Peacey SR. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen? Diabetes Obes Metab 2002;4:106-12.
24. Sandoval DA, Guy DL, Richardson MA, Ertl AC, Davis SN. Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycaemia in type 1 diabetes. Diabetes 2004;53 1798-106.
25. Frier BM, Al-Dujaili EA, Corrall RJ, Pritchard JL, Edwards CR. Autonomic neural control mechanisms and the release of adrenal steroids after hypoglycaemia in man. Horm Metab Res 1984;16(suppl 1): 138-41.
26. Amiel SA. Cognitive function testing in studies of acute hypoglycaemia: rights and wrongs? Diabetologia 1998;41:713-19.
27. Strachan MW, Ewing FM, Frier BM, McCrimmon RJ, Deary IJ. Effects of acute hypoglycaemia on auditory information processing in adults with Type I diabetes. Diabetologia 2003;46:97-105.
28. Madsen BK, Hølmer P, Ibsen H, Christensen NJ. The influence of captopril on the epinephrine response to insulin-induced hypoglycemia in humans. The interaction between the renin-angiotensin system and the sympathetic nervous system. Am J Hypertens 1992;5:361-5.
29. Glorioso N, Dessi-Fulgheri P, Alagna S et al. Angiotensin-converting enzyme inhibition reduces ACTH release due to hypoglycaemia. Clin Exp Hypertens A 1987;9:665-70.
30. Oltmanns KM, Deininger E, Wellhoener P et al. Influence of captopril on symptomatic and hormonal responses to hypoglycaemia in humans. B J Clin Pharmacol 2003:55:347-53.
31. Deininger E, Oltmanns KM, Wellhoener P et al. Losartan attenuates symptomatic and hor-monal responses to hypoglycemia in humans. Clin Pharmacol Ther 2001;70:362-9.
32. Hirsch IB, Heller SR, Cryer PE. Increased symptoms of hypoglycaemia in the standing position in insulin-dependent diabetes mellitus. Clin Sci 1991;80:583-6.
33. Walther T, Olah L, Harms C et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002;16:169-76.
34. Georgiev V, Opitz M. Participation of angiotensin receptors in acute hypoxia in mice. II. Effects of angiotensin II nonpeptide receptor ligands losartan (DuP-753) and PD-123319. Methods Find Exp Clin Pharmacol 1999;21:463-6.
35. Tallroth G, Ryding E, Agardh CD. Regional cerebral blood flow in normal man during insulin-induced hypoglycemia and in the recovery period following glucose infusion. Metabolism 1992;41:717-21.
36. Thomas M, Sherwin RS, Murphy J, Kerr D. Importance of cerebral blood flow to the recognition of and physiological responses to hypoglycemia. Diabetes 1997;46:829-33.
37. Maran A, Cranston I, Lomas J, Macdonald I, Amiel SA. Protection by lactate of cerebral function during hypoglycaemia. Lancet 1994; 343:16-20.
38. Dzau VJ. Tissue renin-angiotensin system: Physiologic and pharmacologic implications. Circulation 1988;77:I1-I3.
39. Montgomery HE, Marshall R, Hemingway H et al. Human gene for physical performance. Nature 1998;393:221-2.
40. Nybo L, Møller K, Pedersen BK, Nielsen B, Secher NH. Association between fatigue and failure to preserve cerebral energy turnover during prolonged exercise. Acta Physiol Scand 2003;179:67-74.
41. Morris AD, Boyle DIR, McMahon AD et al. ACE inhibitor use is associated with hospitalisation for severe hypoglycaemia in patients with diabetes. Diabetes Care 1997;20:1363-7.
42. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349 1787-92.